Cargando…
The effectiveness of Reslizumab in severe asthma treatment: a real-world experience
BACKGROUND: Increased numbers of blood and sputum eosinophils are associated with higher exacerbation frequency and increased asthma severity. In clinical trials, targeting Interleukin-5 has been shown to be a useful therapeutic strategy for patients with severe eosinophilic asthma. METHODS: Twenty-...
Autores principales: | Ibrahim, H., O’Sullivan, R., Casey, D., Murphy, J., MacSharry, J., Plant, B. J., Murphy, D. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6923853/ https://www.ncbi.nlm.nih.gov/pubmed/31861993 http://dx.doi.org/10.1186/s12931-019-1251-3 |
Ejemplares similares
-
Real-World clinical outcomes of asthma patients switched from reslizumab to mepolizumab or benralizumab
por: Walsh, Laura J., et al.
Publicado: (2023) -
‘The Microbiome and the Pathophysiology of Asthma’
por: Sullivan, Ashley, et al.
Publicado: (2016) -
Asthma Control in Patients with Severe Eosinophilic Asthma Treated with Reslizumab: Spanish Real-Life Data
por: Pérez de Llano, Luis A, et al.
Publicado: (2022) -
Non-episodic Angioedema With Eosinophilia Successfully Treated With Reslizumab
por: Chu, Hyunwook, et al.
Publicado: (2019) -
Role of biologics in severe eosinophilic asthma – focus on reslizumab
por: Pelaia, Girolamo, et al.
Publicado: (2016)